CBDV

The main cannabinoid receptor in the brain, responsible for THC’s intoxicating effects, has very low affinity for CBDV. One study measured a CB1 Ki of 14,7 nM for CBDV versus 4,3 nM for CBD, meaning CBD showed approximately 3.4x stronger CB1 binding affinity.

Functional activity is also weak. In a human-receptor signalling study, both CBDV and CBD had a CB1 EC50 above 10,000 nM, indicating very low potency. However, CBDV produced a maximum CB1 response of 68% versus 26% for CBD, approximately 2.6x greater. This shows that CBDV can produce a higher maximum CB1 response than CBD under some laboratory conditions despite binding more weakly. Neither compound showed meaningful THC-like CB1 activity, and CBDV produced no significant THC-like behavioural effects in the tested mice.

CB2 receptor

The main cannabinoid receptor in the immune system, involved in regulating immune cell activity and inflammatory responses. One study measured a CB2 Ki of 574.2 nM for CBDV versus 372.4 nM for CBD, meaning CBD showed approximately 1.5x stronger CB2 binding affinity.

However, receptor binding does not directly predict functional activity. In a human-cell CB2 signalling study, CBDV acted as a CB2 agonist with an EC50 of 12 nM, while CBD did not measurably activate CB2 in the same assay. This suggests that despite binding somewhat more weakly than CBD, CBDV can produce higher maximum CB2 response under some experimental conditions.

Other human-receptor experiments have also identified CBDV as a partial CB2 agonist. CB2 activation could influence immune and inflammatory signalling, but the importance of this mechanism in humans has not yet been fully established.

TRP channels help nerve cells respond to signals such as heat, irritation and changes in how easily cells become activated. CBDV activates and then rapidly desensitises TRPV1, TRPV2 and TRPA1, making the channels less responsive after initial activation. Reported activation EC50 values include 0.42 µM at TRPA1, 3.6 µM at TRPV1 and 7.3 µM at TRPV2. Animal and brain-tissue experiments suggest these mechanisms may help calm overactive nerve-cells, which could contribute to reduced seizure activity, although their importance in humans remains uncertain.

GPR6 is a brain receptor with continuous background activity and is involved in movement and neural signalling. CBDV acts as an inverse agonist, reducing this baseline receptor activity. Laboratory research found a maximum EC50 response of approximately 2.40 µM. Reduced GPR6 activity could potentially influence movement-related and neurological signalling, but its importance and effects in humans remain unknown.

GPR55 helps regulate calcium signalling and neuronal activity. CBDV triggered by GPR55’s signalling, making CBDV a GPR55 antagonist. Reduced GPR55 activity could potentially help calm overactive brain activity, although this has not been shown to produce a specific effect in humans.

TLR4 and MD2 are part of the immune system and help trigger inflammation when they detect potential threats. CBDV binds directly to MD2 and acts as a TLR4 antagonist, reducing this inflammatory response. Laboratory research found that CBDV could substantially reduce this activity at relatively low concentrations. In mice, it also strengthened morphine-related pain relief and reduced the development of morphine tolerance, although these effects have not been confirmed in humans.

CBDV is metabolised in humans to 7-OH-CBDV and subsequently 7-COOH-CBDV. 7-OH-CBDV has shown seizure-reducing effects in animal research and may therefore contribute to some of CBDV’s biological effects, although its importance in humans has not been established.